title: Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.
abstract: BACKGROUND
  Most existing models of smoking cessation treatments have considered a single quit attempt when modelling long-term outcomes.
  
  
  OBJECTIVE
  To develop a model to simulate smokers over their lifetimes accounting for multiple quit attempts and relapses which will allow for prediction of the long-term health and economic impact of smoking cessation strategies.
  
  
  METHODS
  A discrete event simulation (DES) that models individuals' life course of smoking behaviours, attempts to quit, and the cumulative impact on health and economic outcomes was developed. Each individual is assigned one of the available strategies used to support each quit attempt; the outcome of each attempt, time to relapses if abstinence is achieved, and time between quit attempts is tracked. Based on each individual's smoking or abstinence patterns, the risk of developing diseases associated with smoking (chronic obstructive pulmonary disease, lung cancer, myocardial infarction and stroke) is determined and the corresponding costs, changes to mortality, and quality of life assigned. Direct costs are assessed from the perspective of a comprehensive US healthcare payer ($US, 2012 values). Quit attempt strategies that can be evaluated in the current simulation include unassisted quit attempts, brief counselling, behavioural modification therapy, nicotine replacement therapy, bupropion, and varenicline, with the selection of strategies and time between quit attempts based on equations derived from survey data. Equations predicting the success of quit attempts as well as the short-term probability of relapse were derived from five varenicline clinical trials.
  
  
  RESULTS
  Concordance between the five trials and predictions from the simulation on abstinence at 12 months was high, indicating that the equations predicting success and relapse in the first year following a quit attempt were reliable. Predictions allowing for only a single quit attempt versus unrestricted attempts demonstrate important differences, with the single quit attempt simulation predicting 19 % more smoking-related diseases and 10 % higher costs associated with smoking-related diseases. Differences are most prominent in predictions of the time that individuals abstain from smoking: 13.2 years on average over a lifetime allowing for multiple quit attempts, versus only 1.2 years with single quit attempts. Differences in abstinence time estimates become substantial only 5 years into the simulation. In the multiple quit attempt simulations, younger individuals survived longer, yet had lower lifetime smoking-related disease and total costs, while the opposite was true for those with high levels of nicotine dependence.
  
  
  CONCLUSIONS
  By allowing for multiple quit attempts over the course of individuals' lives, the simulation can provide more reliable estimates on the health and economic impact of interventions designed to increase abstinence from smoking. Furthermore, the individual nature of the simulation allows for evaluation of outcomes in populations with different baseline profiles. DES provides a framework for comprehensive and appropriate predictions when applied to smoking cessation over smoker lifetimes.
authors.affiliation: United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington Office Park, Lexington, MA 02420, USA. denis.getsios@unitedbiosource.com
authors.forename: Denis
authors.initials: D
authors.lastname: Getsios
authors.forename: Jenő P
authors.initials: JP
authors.lastname: Marton
authors.forename: Nikhil
authors.initials: N
authors.lastname: Revankar
authors.forename: Alexandra J
authors.initials: AJ
authors.lastname: Ward
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Willke
authors.forename: Dale
authors.initials: D
authors.lastname: Rublee
authors.forename: K Jack
authors.initials: KJ
authors.lastname: Ishak
authors.forename: James G
authors.initials: JG
authors.lastname: Xenakis
mesh_terms: D000328:Adult; D001552:Benzazepines / Q000191:economics / Q000627:therapeutic use; D016642:Bupropion / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003198:Computer Simulation; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D018803:Models, Economic; D011788:Quality of Life; D011810:Quinoxalines / Q000191:economics / Q000627:therapeutic use; D012008:Recurrence; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods*; D014029:Tobacco Use Disorder / Q000150:complications / Q000188:drug therapy* / Q000191:economics* / Q000517:prevention & control; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline